Folgen
Dan Peer
Dan Peer
Prof. of NanoMedicine and Immunology, Tel Aviv University
Bestätigte E-Mail-Adresse bei post.tau.ac.il
Titel
Zitiert von
Zitiert von
Jahr
Nanocarriers as an emerging platform for cancer therapy
D Peer, JM Karp, S Hong, OC Farokhzad, R Margalit, R Langer
Nano-enabled medical applications, 61-91, 2020
95882020
Progress and challenges towards targeted delivery of cancer therapeutics
D Rosenblum, N Joshi, W Tao, JM Karp, D Peer
Nature communications 9 (1), 1410, 2018
17782018
Systemic leukocyte-directed siRNA delivery revealing cyclin D1 as an anti-inflammatory target
D Peer, EJ Park, Y Morishita, CV Carman, M Shimaoka
Science 319 (5863), 627-630, 2008
5772008
Nanoparticle hydrophobicity dictates immune response
DF Moyano, M Goldsmith, DJ Solfiell, D Landesman-Milo, OR Miranda, ...
Journal of the American Chemical Society 134 (9), 3965-3967, 2012
4762012
The systemic toxicity of positively charged lipid nanoparticles and the role of Toll-like receptor 4 in immune activation
R Kedmi, N Ben-Arie, D Peer
Biomaterials 31 (26), 6867-6875, 2010
4632010
Polysaccharides as building blocks for nanotherapeutics
S Mizrahy, D Peer
Chemical Society Reviews 41 (7), 2623-2640, 2012
4282012
Selective gene silencing in activated leukocytes by targeting siRNAs to the integrin lymphocyte function-associated antigen-1
D Peer, P Zhu, CV Carman, J Lieberman, M Shimaoka
Proceedings of the National Academy of Sciences 104 (10), 4095-4100, 2007
3302007
Nanoparticles for imaging, sensing, and therapeutic intervention
LK Bogart, G Pourroy, CJ Murphy, V Puntes, T Pellegrino, D Rosenblum, ...
ACS nano 8 (4), 3107-3122, 2014
3182014
CRISPR-Cas9 genome editing using targeted lipid nanoparticles for cancer therapy
D Rosenblum, A Gutkin, R Kedmi, S Ramishetti, N Veiga, AM Jacobi, ...
Science advances 6 (47), eabc9450, 2020
3122020
Mechanisms and barriers in cancer nanomedicine: addressing challenges, looking for solutions
TJ Anchordoquy, Y Barenholz, D Boraschi, M Chorny, P Decuzzi, ...
ACS nano 11 (1), 12-18, 2017
3072017
Loading mitomycin C inside long circulating hyaluronan targeted nano‐liposomes increases its antitumor activity in three mice tumor models
D Peer, R Margalit
International Journal of Cancer 108 (5), 780-789, 2004
2852004
Tumor-targeted hyaluronan nanoliposomes increase the antitumor activity of liposomal doxorubicin in syngeneic and human xenograft mouse tumor models
D Peer, R Margalit
Neoplasia (New York, NY) 6 (4), 343, 2004
2622004
Hyaluronan-coated nanoparticles: the influence of the molecular weight on CD44-hyaluronan interactions and on the immune response
S Mizrahy, SR Raz, M Hasgaard, H Liu, N Soffer-Tsur, K Cohen, R Dvash, ...
Journal of controlled release 156 (2), 231-238, 2011
2472011
RNAi-mediated CCR5 silencing by LFA-1-targeted nanoparticles prevents HIV infection in BLT mice
SS Kim, D Peer, P Kumar, S Subramanya, H Wu, D Asthana, K Habiro, ...
Molecular therapy 18 (2), 370-376, 2010
2442010
Cell specific delivery of modified mRNA expressing therapeutic proteins to leukocytes
N Veiga, M Goldsmith, Y Granot, D Rosenblum, N Dammes, R Kedmi, ...
Nature communications 9 (1), 4493, 2018
2222018
A modular platform for targeted RNAi therapeutics
R Kedmi, N Veiga, S Ramishetti, M Goldsmith, D Rosenblum, N Dammes, ...
Nature nanotechnology 13 (3), 214-219, 2018
2172018
RNAi-based nanomedicines for targeted personalized therapy
A Daka, D Peer
Advanced drug delivery reviews 64 (13), 1508-1521, 2012
1912012
Special delivery: targeted therapy with small RNAs
D Peer, J Lieberman
Gene therapy 18 (12), 1127-1133, 2011
1842011
Paving the road for RNA therapeutics
N Dammes, D Peer
Trends in Pharmacological Sciences 41 (10), 755-775, 2020
1742020
Next-generation lipids in RNA interference therapeutics
S Rietwyk, D Peer
ACS nano 11 (8), 7572-7586, 2017
1732017
Das System kann den Vorgang jetzt nicht ausführen. Versuchen Sie es später erneut.
Artikel 1–20